- US-listed companies
- Lyell Immunopharma, Inc.
- Income statement
Lyell Immunopharma, Inc.LYEL
Market cap
$11B
P/E ratio
| 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 11 | 85 | 0 | 0 |
| Revenue growth (%) | - | |||
| Research & development | 139 | 159 | 183 | - |
| Operating margin (%) | ||||
| Operating income | -215 | -187 | -247 | -359 |
| Operating expenses | 225 | 272 | 247 | 359 |
| Net income | -250 | -183 | -235 | -343 |
| Net income margin (%) | ||||
| Earnings per share | -1.84 | -0.74 | -0.93 | -1.31 |
| Diluted EPS | -1.84 | -0.74 | -0.93 | -1.31 |
| EBITDA | ||||
| EBITDA margin (%) |